ニソルジピン
Nisoldipine
基本情報
- CAS
63675-72-9- 標準SMILES
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]- InChIKey
VKQFCGNPDRICFG-UHFFFAOYSA-N- 分子式
- C20H24N2O6
- 平均分子量
- 388.4 g/mol
- 単同位体質量
- 388.16343649
概要
Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate is a dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris. It is a member of dicarboxylic acids and O-substituted derivatives, a methyl ester, a C-nitro compound, a dihydropyridine and a diester.
名称と識別子
- 優先名称
- Nisoldipine
- IUPAC
- 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- 現地名
- ニソルジピン
- 英語名
- Nisoldipine
- 分子式
- C20H24N2O6
- 分子量
- 388.41
名称と別名
nisoldipine63675-72-9SularNisocorBaymycardNisoldipinBay k 5552NisoldipinoNisoldipinumBay-k-5552Geomatrix 16eDTXSID0023371
名称をさらに表示
2,6-ジメチル-4-(2-ニトロフェニル)-1,4-ジヒドロピリジン-3,5-ジカルボン酸3-イソブチル5-メチルニソルジピン1,4-ジヒドロ-2,6-ジメチル-4-(2-ニトロフェニル)-3,5-ピリジンジカルボン酸3-メチル5-イソブチルリオハードニノバルシンニソミナードニカミールバイミカード1,4-ジヒドロ-2,6-ジメチル-4-(2-ニトロフェニル)-3,5-ピリジンジカルボン酸イソブチルメチルニソルジピン (JAN)3-メチル 5-(2-メチルプロピル) 2,6-ジメチル-4-(2-ニトロフェニル)-1,4-ジヒドロピリジン-3,5-ジカルボキシラート1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLIC ACID METHYL 2-METHYLPROPYL ESTERNisoLSyseorSYSCORNORVASCNikamealZADIPINA
Nisoldipine (stn)Nisoldipine SR4I8HAB65SZNSC-7591063,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl esterDTXCID4033713-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester, (+-)-
物性
構造計算による物性
- XLogP
- 3.3
- 極性表面積
- 110 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 7
- 回転可能結合数
- 7
- 重原子数
- 28
- 形式電荷
- 0
- 複雑度
- 704
実験および物理化学的性質
DrugsPharmaceuticals
LogP
3.1
3.59
Solubility5.77e-03 g/L
Human Drugs
Breast Feeding; Lactation; Antihypertensive Agents; Calcium Channel Blockers; Vasodilator Agents;
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physical DescriptionSolid
Collision Cross Section
195.5 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID0023371]
193.15 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
187.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 147 · 147-148°C
- 沸点
- 503.3 · 503.3±50.0 °C(Predicted)
- 比重(密度)
- 1.205 · 1.205±0.06 g/cm3(Predicted)
- 貯蔵温度
- room temp
- 溶解性
- 10 mg/mL · DMSO：>10mg/mL
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P273, P280, P301+P317, P302+P352, P317, P318, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 69 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Hazard Classes and CategoriesAcute Tox. 4 (100%)
毒性情報
Adverse Effects
Though nisoldipine is well-tolerated among patients, the drug does have some side effects mainly associated with its vasodilating property. Common adverse effects associated with nisoldipine include flushing, vasodilation (4%), hypotension, syncope, peripheral edema (7% to 29%,dose-related), headache (22%), dizziness (3% to 10%), and nausea (2%).
Toxicity Summary
Toxicity due to nisoldipine is diagnosed based on clinical status and history. As described above, hypotension with reflex tachycardia can occur when patients take excessive doses of dihydropyridine calcium channel blockers such as nisoldipine. In some severe cases of nisoldipine toxicity, the clinician will note hypotension with bradycardia. Secondary findings of confusion, heart failure, and abnormal ECG changes such as PR prolongation can indicate toxicity. Additionally, hyperglycemia in patients without diabetes can suggest calcium channel blockers poisoning.
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Nisoldipine
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
化学と産業
薬理情報
ATC Code
C - Cardiovascular system
QC - Cardiovascular system
Protein Binding99%
Pharmacodynamics
Nisoldipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of Action
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Biological Half-Life7-12 hours
Metabolism/Metabolites
Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4.
関連反応
1 件
化合物ノート
読み込み中…